Bone Biologics (OTC:BBLG) Stock Price Down 9.8%

Bone Biologics Co. (OTC:BBLGGet Free Report) shares dropped 9.8% on Tuesday . The stock traded as low as $1.00 and last traded at $1.10. Approximately 147,820 shares were traded during trading, an increase of 51% from the average daily volume of 97,920 shares. The stock had previously closed at $1.22.

Bone Biologics Stock Down 9.8 %

The stock has a market cap of $1.21 million, a price-to-earnings ratio of -0.02 and a beta of 0.31. The firm’s 50 day moving average is $1.55 and its two-hundred day moving average is $2.47.

About Bone Biologics

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.

Recommended Stories

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with's FREE daily email newsletter.